A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy

Supportive Care in Cancer

Volumn 5, Issue 1, 1997, Pages 22-30

  Chevallier, B ^a   Cappelaere, P ^b   Splinter, T ^c   Fabbro, M ^d   Wendling, J L ^e   Cals, L ^f   Catimel, G ^g   Giovannini, M ^h   Khayat, D ⁱ   Bastit, P ^a   Claverie, N ^j  

^a CENTRE HENRI BECQUEREL   (France)

^b CENTRE OSCAR LAMBRET   (France)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d CENTRE VAL D AURELLE   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f Centre de Gerontologie Georges CLEMENCEAU   (France)

^g CENTRE LÉON BÉRARD   (France)

^h INSTITUT PAOLI CALMETTES   (France)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^j SANOFI   (France)

more..

Author keywords

5 HT3 receptor antagonist; Antiemetic; Cisplatin; Dolasetron; Metoclopramide

Indexed keywords

CISPLATIN; DOLASETRON MESILATE; METOCLOPRAMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

EID: 8244261276     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01681958     Document Type: Article

References (41)

1. 3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis. Drugs 42:551-568
2. Allen JC, Gralla R, Reilly L, et al (1985) Metoclopramide: dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy. J Clin Oncol 3:1136-1141
3. 2) chemotherapy (abstract). Support Care Cancer 5:338
4. Bateman DN, Rawlins MD, Simpson JM (1985) Extrapyramidal reactions with metoclopramide. BMJ 291:930-932
5. 3 receptor antagonist. Drug Dev Res 34:289-296
6. 3 antagonists MDL 73147EF (dolasetron mesylate) and MDL 74156 in NG108-15 neuroblastoma × glioma cells. Eur J Pharmacol 219:9-13
7. Boxenbaum H, Gillespie T, Heck K, et al (1992) Human dolasetron pharmacokinetics. I. Disposition following single-dose intravenous administration to normal male subjects. Biopharm Drug Dispos 13:693-701
8. 3 antagonist, in cancer patients treated with cisplatin. Am J Clin Oncol 17:97-102
9. Cooper S, Georgiou V (1992) The impact of cytotoxic chemotherapy - perspectives from patients, specialists and nurses. Eur J Cancer 28A [Suppl 1]:S36-S38
10. Cunningham D, Soukop M, Gilchrist NL, et al (1985) Randomised trial of intravenous high-dose metoclopramide and intramuscular chlorpromazine in controling nausea and vomiting induced by cytotoxic drugs. BMJ 290:604-605
11. D'Aquisto R, Tyson LB, Gralla RJ, et al (1986) The influence of chronic high alcohol intake on chemotherapy-induced nausea and vomiting (abstract). Proc Am Soc Clin Oncol 5:257
12. De Mulder PHM, Seynaeve C, Vermorken JB, et al (1990) Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 113:834-840
13. Galvan M, Gittos MW, Fatmi M (1993) Dolasetron mesylate. Drugs Future 18:506-509
14. Gordon CJ, Pazdur R, Ziccarelli A, et al (1989) Metoclopramide versus metoclopramide and lorazepam: superiority of combined therapy in the control of cisplatin-induced emesis. Cancer 63:578-582
15. Gralla RJ (1993) Current issues in the management of nausea and vomitine. Ann Oncol 4 [Suppl 3]:S3-S7
16. Gralla RJ, Itri LM, Pisko SE, et al (1981) Antiemetic efficacy of high-dose metoclopramide: randomised trials with placebo and prochlorperazine in patients with chemotherapy induced nausea and vomiting. N Engl J Med 305:905-909
17. Gralla RJ, Tyson LB, Kris MG, et al (1987) The management of chemotherapy-induced nausea and vomiting. Med Clin North Am 72:289-300
18. Grunberg SM, Hesketh PJ (1993) Control of chemotherapy-induced emesis. N Engl J Med 329:1790-1796
19. Grunberg SM, Stevenson LL, Russell CA, et al (1989) Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 7:1137-1141
20. Hainsworth J, Harvey W, Pendergrass K, et al (1991) A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol 9:721-728
21. Harman GS, Omura GA, Ryan K, Hainsworth JD, Cramer MB, Hahne WF (1996) A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis. Cancer Chemother Pharmacol 38:323-328
22. Hesketh PJ (1991) Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst 83:613-620
23. Hesketh PJ, Gandara DR, Hesketh AM, et al (1996) Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide. Support Care Cancer 4:141-146
24. 3-receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann Oncol 4:481-484
25. Kris MG, Gralla RJ, Tyson LB, et al (1985) Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients. Cancer 55:527-534
26. Kris MG, Gralla RJ, Clark RJ, et al (1987) Antiemetic control and prevention of side effects of anticancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. Cancer 60:2816-2822
27. Kris MG, Grunberg SM, Gralla RJ, et al (1994) Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J Clin Oncol 12:1045-1049
28. Lazlo J (1983) Nausea and vomiting as major complications of cancer chemotherapy. Drugs 25 [Suppl 1]:1-7
29. Markham A, Sorkin EM (1993) Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomitins. Drugs 45:931-952
30. Marty M, Pouillart P, Scholl S, et al (1990) Comparison of the 5-hydroxytryptamine-3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 322:816-821
31. Merrouche Y, Catimel G, Rebattu P, et al (1994) A phase I antiemetic study of MDL 73,147EF, a novel 5-hydroxytryptamine antagonist in cancer patients receiving emetogenic chemotherapy. Ann Oncol 5:549-551
32. 3 receptors. Drug Dev Res 28:87-93
33. Navari RM, Kaplan HG, Gralla RJ, et al (1994) Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 12:2204-2210
34. Peace KM (1990) Statistical issues in drug research and development. Dekker, New York
35. Riviere A (1994) Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. Br J Cancer 69:967-971
36. Roila F, Tonato M, Basurto C, et al (1987) Anti-emetic activity of high-dose metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. J Oncol 5:141-149
37. Sledge GW Jr, Einhorn L, Nagy C, et al (1992) Phase III double-blind comparison of intravenous ondansetron and metodopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer 70:2524-2528
38. Sullivan JR, Leyden MJ, Bell R (1983) Decreased cisplatin induced nausea and vomiting with chronic alcohol ingestion. N Engl J Med 309:796-797
39. Tortorice PV, O'Connell MB (1990) Management of chemotherapy-induced nausea and vomiting. Pharmacotherapy 10:129-145
40. Warrington PS, Allan SG, Cornbleet MA, et al (1986) Optimising antiemetics in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high-dose metoclopramide in emesis induced by cisplatin. BMJ 293:1334-1337
41. Yielding A, Bertoli L, Eisenberg P, et al (1996) Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy. Am J Clin Oncol (in press)